S-1/A: Enveric Biosciences Files for Offering of Common Stock and Warrants

Enveric Biosciences is seeking to raise capital through an offering of common stock, pre-funded warrants, and accompanying Series A and Series B warrants.

Summary

• Enveric Biosciences has filed a registration statement for an offering of up to 1,204,819 shares of common stock, along with Series A and Series B warrants.
• The company is also offering pre-funded warrants to certain purchasers who would exceed ownership limits if they purchased common stock directly.
• The assumed combined public offering price for each share of common stock, together with each Series A warrant and Series B warrant to purchase one share of common stock, is $4.15.
• The Series A warrants will have an exercise price of $ per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, or immediately if certain pricing conditions are met, and will expire five years from the initial exercise date.
• The Series B warrants will have an exercise price of $ per share and will be exercisable beginning on the initial exercise date, and will expire eighteen months from the initial exercise date.
• The pre-funded warrants will be exercisable for one share of common stock at an exercise price of $0.0001 per share and will be exercisable upon issuance and may be exercised at any time until all of the pre-funded warrants are exercised in full.
• The offering is expected to terminate on February 13, 2025, unless the company decides to terminate it earlier.
• H.C. Wainwright & Co., LLC is acting as the exclusive placement agent for the offering and will receive a cash fee equal to 7.0% of the gross proceeds raised in this offering, a management fee equal to 1.0% of the gross proceeds raised in this offering, and warrants to purchase a number of shares of common stock equal to 7.0% of the aggregate number of shares of common stock and pre-funded warrants being offered at an exercise price equal to 125% of the combined public offering price per share of common stock and accompanying warrant.

Sentiment

Score: 4

Explanation: The document presents a mix of positive and negative aspects. While the company is seeking to raise capital, there are significant risks and uncertainties associated with the company's business and the offering itself. The going concern warning and the lack of revenue are significant concerns.

Positives

• The offering provides Enveric with a potential source of capital to fund its operations and development programs.
• The inclusion of warrants may make the offering more attractive to investors.
• The pre-funded warrants offer flexibility for investors who may have ownership limitations.

Negatives

• The offering is a best-efforts offering, and there is no guarantee that the company will raise the full amount of capital sought.
• The warrants and pre-funded warrants are not listed on any exchange, which may limit their liquidity.
• The offering price may be at a discount to the current market price of the common stock.

Risks

• The company will require substantial additional funding, which may not be available on acceptable terms.
• The company has broad discretion in how it uses the proceeds of this offering and may not use these proceeds effectively.
• The company's common stock has often been thinly traded, so investors may be unable to sell at or near ask prices or at all.
• If the company is required to obtain Warrant Stockholder Approval, until it is able to receive such approval the warrants will not be exercisable, and if it is unable to obtain such approval the warrants will have no value.
• The company is dependent on the success of its prospective product candidates, which are in early stages of development, and there can be no assurances that any such prospects will reach a particular stage in development, receive regulatory approval or be successfully commercialized.
• The company may encounter difficulties that may delay, suspend or scale back its efforts to advance additional early research programs through preclinical development and IND application filings and into clinical development.
• Catastrophic events could have a material adverse effect on the company's business, including current plans for product development, as well as any currently ongoing preclinical studies and clinical trials and any future studies or other development or commercialization activities.
• The company has significant and increasing liquidity needs and may require additional funding.
• The company depends on its current key personnel.
• There has been limited study on the effects of psychedelic-inspired drug candidates, and future clinical research studies may lead to conclusions that dispute or conflict with the company's understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing, and social acceptance of psychedelics.
• The company expects to face intense competition, often from companies with greater resources and experience than the company.
• The company's current and future preclinical and clinical studies may be conducted outside the United States, and the FDA may not accept data from such studies to support any NDAs the company may submit after completing the applicable developmental and regulatory prerequisites.
• Because the results of preclinical studies and earlier clinical trials are not necessarily predictive of future results, the company may not have favorable results in its planned and future clinical trials.
• Regulatory approval is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated, and the company may be subject to fines, penalties or injunctions if it is determined to be promoting the use of its products for unapproved or off-label uses.
• Business interruptions could delay the company in the process of developing its product candidates.
• The company's employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and legal requirements.
• The company's proprietary information, or that of its customers, suppliers and business partners, may be lost or the company may suffer security breaches.
• Failure of the company's information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt the operation of its business.
• The company's operating results may vary significantly in future periods.
• The company has significant and increasing liquidity needs and may require additional funding.
• The company may rely on third parties to plan and conduct preclinical and clinical trials.
• The company may rely on third-party contract manufacturers.
• Termination or non-renewal of key licenses and agreements.
• Negative results from clinical trials or studies of others and adverse safety events involving the company's drug candidates.
• Clinical trials of the company's drug candidates may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or not otherwise produce positive results.
• Raw materials requiring regulatory approval.
• Possible increase in costs beyond what is currently expected as a result of regulatory review.
• The company has never been profitable, has no products approved for commercial sale, and has generated no reported revenue.
• The company has no commercial licensing, marketing or distribution experience and will have to invest significant resources to develop those capabilities or enter into acceptable third-party sales and marketing transactions.
• The company may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
• Changes in patent law and its interpretation could diminish the value of patents in general, thereby impairing the company's ability to protect its drug candidates.
• Failure to manage growth.
• Insurance and uninsured risks.
• Litigation.
• Conflicts of interest.
• The psychedelicinspired medicines industry and market are relatively new in this industry and the market may not continue to exist or grow as anticipated.
• The psychedelic and psychedelic-inspired medicine market will face specific marketing challenges given the psychedelic products status as a controlled substance which resulted in past and current public perception that the products have negative health and lifestyle effects and have the potential to cause physical and social harm due to psychoactive and potentially addictive effects.
• The psychedelics-inspired medicines industry and market are relatively new, and the industry may not succeed in the long term.
• The company's psychedelic-inspired durg candidates may generate public controversy.
• The psychedelic-inspired medicine industry is difficult to quantify and investors will be reliant on their own estimates of the accuracy of market data.
• The psychedelic-inspired medicine and biotechnology industries are experiencing rapid growth and increased competition.
• Changes in legislation, regulations and guidelines.
• The company's current and prospective product candidates, and the development thereof, are or will be subject to the various federal and state laws and regulations relating to the safety and efficacy of health products, such as drugs and medical devices.
• The psychedelic-inspired drug candidates the company is developing or may develop in the future may be subject to controlled substance laws and regulations in the United States and other countries where the product will be marketed, and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results of the company's business operations and its financial condition.
• Regulatory approval is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated, and the company may be subject to fines, penalties or injunctions if it is determined to be promoting the use of its products for unapproved or off-label uses.
• Clinical trials are expensive, time-consuming, uncertain and susceptible to change, delay or termination.
• The company may rely on third parties to plan and conduct preclinical and clinical trials.
• The company may rely on third-party contract manufacturers.
• Difficulty or delays in enrolling patients in clinical trials may result in delay or prevention of necessary regulatory approvals.
• Any failure by the company to comply with existing regulations could harm its reputation and operating results.
• The company may be required to repurchase the warrants, which may prevent or deter a third party from acquiring the company.
• The company may be required to repurchase the warrants, which may prevent or deter a third party from acquiring the company.
• FINRA sales practice requirements may limit a stockholders ability to buy and sell the company's securities.
• The company's independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.
• The company will be unable to continue to operate for the foreseeable future without additional capital.
• If the company does not maintain a current and effective prospectus relating to the common stock issuable upon exercise of the warrants and pre-funded warrants, public holders will only be able to exercise such warrants and pre-funded warrants on a cashless basis.
• The warrants are speculative in nature.
• This is a best efforts offering. No minimum amount of securities is required to be sold, and the company may not raise the amount of capital it believes is required for its business plans, including its near-term business plans.
• The warrants are speculative in nature.
• The company may be required to repurchase the warrants, which may prevent or deter a third party from acquiring the company.
• FINRA sales practice requirements may limit a stockholders ability to buy and sell the company's securities.
• If the company does not maintain a current and effective prospectus relating to the common stock issuable upon exercise of the warrants and pre-funded warrants, public holders will only be able to exercise such warrants and pre-funded warrants on a cashless basis.
• The warrants are speculative in nature.
• This is a best efforts offering. No minimum amount of securities is required to be sold, and the company may not raise the amount of capital it believes is required for its business plans, including its near-term business plans.

Future Outlook

The company intends to use the net proceeds from this offering for product development, working capital, and general corporate purposes.

Industry Context

The document indicates that the company is operating in the biotechnology industry, specifically focusing on neuroplastogenic small-molecule therapeutics for mental health disorders, which is a growing area of interest.

Comparison to Industry Standards

• The document does not provide specific details on comparable companies or projects.
• However, the company's focus on psychedelic-inspired drug candidates and neuroplastogens aligns with current trends in the biotechnology industry.
• The company's reliance on a placement agent for the offering is a common practice in the industry.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Investors in this offering face risks associated with the company's financial condition and the speculative nature of the securities.
• Employees may be affected by the company's financial situation and any potential cost-cutting measures.

Next Steps

• The company intends to use the net proceeds from this offering for product development, working capital, and general corporate purposes.
• The company will seek Stockholder Approval for the issuance of shares of common stock issuable upon exercise of the warrants, if required.
• The company will apply to list or quote all of the Shares and Warrant Shares on the Trading Market.

Key Dates

Keywords

common stock, warrants, pre-funded warrants, offering, biotechnology, neuroplastogenic, mental health, H.C. Wainwright, capital raise, psychedelic-inspired